T

The Royal Marsden Hospital | Sutton - GI Lymphoma Research Unit

Research site

(Unclaimed)

Location

Downs Road, Sutton, Sutton, England

Site insights

Top conditions

Top treatments

Afatinib

BIBW 2992

Docetaxel

Oxaliplatin

Bevacizumab

Trastuzumab

Estrogen

Cetuximab

Doxorubicin

Ipatasertib

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

4 of 41 total trials

A Study of Autogene Cevumeran (RO7198457) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors

This is a Phase 1a/1b, open-label, multicenter, global, dose-escalation study designed to evaluate the safety, tolerability, immune response, and pha...

Active, not recruiting

Bladder Cancer

Melanoma

Drug: Autogene cevumeran

Drug: Atezolizumab

A Study of GDC-9545 Alone or in Combination With Palbociclib and/or Luteinizing Hormone-Releasing Hormone (LHRH) Agonist in Locally Advanced or Metastatic Estrogen Receptor-Positive Breast Cancer

This study will evaluate the safety, pharmacokinetic (PK), pharmacodynamic (PD) activity, and preliminary anti-tumor activity of GDC-9545 as a single...

Active, not recruiting

Breast Cancer

Drug: Palbociclib

Drug: LHRH Agonist

A Study to Assess the Anti-Tumor Activity and Safety of Odronextamab in Patients With B-cell Non-Hodgkin Lymphoma That Have Been Previously Treated (ELM-2)

Primary objective is to assess the anti-tumor activity of single agent odronextamab as measured by the objective response rate (ORR) according to the...

Enrolling

B-cell Non-Hodgkin Lymphoma (NHL)

Drug: Odronextamab

Trial of Pembrolizumab in Metastatic Castration Resistant Prostate Cancer (PERSEUS1)

PERSEUS1 is an open-label, single arm, phase II trial evaluating the efficacy of Pembrolizumab in metastatic castration resistant prostate cancer (mC...

Enrolling

Castration-resistant Prostate Cancer

Drug: Pembrolizumab